Enjoy complimentary customisation on priority with our Enterprise License!
The leuprolide acetate market size is forecast to increase by USD 1.43 billion at a CAGR of 9.7% between 2023 and 2028. The market is experiencing significant growth due to the rising prevalence of advanced prostate cancer and the increasing popularity of long-acting suspension formulations, such as Eligard and Lupron Depot. These formulations offer convenience and effectiveness for patients undergoing hormone therapy. Additionally, the preference for minimally invasive treatments for conditions like endometriosis, anemia, and uterine fibroids is driving the demand for Leuprolide Acetate as an alternative to surgery. The use of advanced drug delivery systems, such as Camcevi, further enhances the market's potential. Intramuscular injections remain a common administration route for Leuprolide Acetate, ensuring patient compliance and convenience. Overall, the market's growth is attributed to these factors, making it an attractive investment opportunity for industry players.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.